This Viewpoint reviews the development of immune checkpoint inhibitors as a new drug class for treating cancer, and discusses future directions including development of commercial assays for identifying response-to-treatment biomarkers and the use of combination regimens to improve response.
No takes yet. Share an insight, caveat, or question.
Suzanne L. Topalian (2017) studied this question.